Valuation: Stoke Therapeutics, Inc.

Market Cap 1.81B 1.58B 1.46B 1.34B 2.53B 174B 2.59B 17.44B 6.86B 85.33B 6.79B 6.65B 294B P/E 2026 *
-8.83x
P/E 2027 * -9.17x
Enterprise Value 1.61B 1.41B 1.3B 1.2B 2.26B 156B 2.31B 15.57B 6.12B 76.17B 6.06B 5.93B 262B EV / Sales 2026 *
66.4x
EV / Sales 2027 * 33.4x
Free-Float
96.18%
Yield 2026 *
-
Yield 2027 * -
1 day-0.21%
1 week-7.43%
Current month-11.22%
1 month-4.00%
3 months-22.06%
6 months+1.22%
Current year-8.48%
1 week 28.35
Extreme 28.35
31.6
1 month 28.35
Extreme 28.35
33.72
Current year 25.21
Extreme 25.21
40.22
1 year 12.25
Extreme 12.25
40.22
3 years 3.35
Extreme 3.35
40.22
5 years 3.35
Extreme 3.35
40.22
10 years 3.35
Extreme 3.35
71.58
Manager TitleAgeSince
Chief Executive Officer 60 2025-03-18
Chief Tech/Sci/R&D Officer 54 2014-05-31
Director of Finance/CFO 49 2024-05-06
Director TitleAgeSince
Chairman 65 2015-06-30
Director/Board Member 67 2014-05-31
Director/Board Member 72 2015-08-31
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Chief Technology Officer

-7,228 0.0122%
6/16/26 Sell

General Counsel

-1,457 0.0023%
6/3/26 Free

Chairman

17,786 0.0286%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-7.43%+135.22%+178.79% 1.81B
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +0.15%-0.71%+213.32%+179.40% 20.8B
Weighted average by Cap. +0.24%+0.29%+171.09%+187.34%

Financials

2026 *2027 *
Net sales 24.32M 21.25M 19.61M 18.08M 34.07M 2.34B 34.83M 234M 92.19M 1.15B 91.33M 89.32M 3.95B 46.5M 40.64M 37.5M 34.57M 65.15M 4.48B 66.6M 448M 176M 2.19B 175M 171M 7.55B
Net income -211M -184M -170M -157M -295M -20.3B -302M -2.03B -799M -9.94B -792M -774M -34.22B -212M -185M -171M -157M -297M -20.4B -303M -2.04B -803M -9.99B -796M -778M -34.4B
Net Debt -194M -170M -157M -144M -272M -18.72B -278M -1.87B -737M -9.17B -730M -714M -31.56B -256M -224M -207M -190M -359M -24.67B -367M -2.47B -971M -12.08B -962M -941M -41.59B
Logo Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Employees
170
Date Price Change Volume
26-07-17 US$29.05 -0.21% 413,964
26-07-16 US$29.11 -2.67% 555,052
26-07-15 US$29.91 +2.68% 592,390
26-07-14 US$29.13 -1.12% 560,309
26-07-13 US$29.46 -6.12% 580,470
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
29.05USD
Average target price
45.82USD
Spread / Average Target
+57.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STOK Stock